Evidence map›Paper›PMID 41774421›Full record

ArticleAnnals of nuclear medicine2026

Predictive value of the

Esra Ciftci, Burak Akovali, Hatice Sariyildiz Gumusgoz, Burcin Karasah Erkek

Abstract read
In one paragraph

Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Esra CiftciFaculty of Medicine, Department of Nuclear Medicine, Research and Training Hospital, Sakarya University, Sakarya, Turkey. esraciftci@sakarya.edu.tr.ORCID http://orcid.org/0000-0001-6106-7733
Burak AkovaliFaculty of Medicine, Department of Nuclear Medicine, Çanakkale Onsekiz Mart University, Canakkale, Turkey.ORCID http://orcid.org/0000-0001-8415-0839
Hatice Sariyildiz GumusgozFaculty of Medicine, Department of Nuclear Medicine, Research and Training Hospital, Sakarya University, Sakarya, Turkey.ORCID http://orcid.org/0000-0001-6410-0746
Burcin Karasah ErkekDepartment of Nuclear Medicine, Agrı Training and Research Hospital, Agrı, Turkey.ORCID http://orcid.org/0000-0002-4972-0936

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePathological upgrading is common in men with ISUP Grade Group (GG) 1 prostate cancer due to sampling limitations. MATERIALS AND

methodsThis retrospective study included 71 patients with biopsy-proven GG1 prostate adenocarcinoma, PSA < 20 ng/mL, and

resultsPathological upgrading occurred in 45/71 patients (63.4%). Upgrading rates increased markedly across PRIMARY score categories: 25% for scores ≤ 3, 81.3% for score 4, and 100% for score 5 (p < 0.001). A PRIMARY score ≥ 4 demonstrated excellent diagnostic performance (AUC = 0.979), with 97.8% sensitivity, 88.5% specificity, 93.6% PPV, 95.6% NPV, and 94.3% accuracy. SUVmax (AUC = 0.944) and PI-RADS ≥ 4 (AUC = 0.721) were also associated with upgrading; however, in multivariate analysis, only the PRIMARY score remained an independent predictor (OR: 19.9; 95% CI: 2.92-135.28; p = 0.002).

conclusion"The

Indexed as

Edetic AcidOligopeptidesOrganometallic CompoundsPositron Emission Tomography Computed TomographyProstatectomyProstate-Specific AntigenProstatic NeoplasmsAgedGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedNeoplasm GradingPredictive Value of TestsRetrospective StudiesEdetic Acidgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesOligopeptidesOrganometallic CompoundsProstate-Specific Antigen68Ga-PSMA-11 PET/CTISUP Grade Group 1Pathological upgradingPRIMARY scoreProstate cancer

Identifiers

PMID41774421
PMCPMC13283149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.